Provided by Tiger Fintech (Singapore) Pte. Ltd.

TriSalus Life Sciences Inc.

4.18
-0.0500-1.18%
Post-market: 4.180.00000.00%16:10 EDT
Volume:60.25K
Turnover:253.10K
Market Cap:158.17M
PE:-3.67
High:4.31
Open:4.18
Low:4.05
Close:4.23
Loading ...

Company Profile

Company Name:
TriSalus Life Sciences Inc.
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
110
Office Location:
6272 West 91st Avenue,Westminster,Colorado,United States
Zip Code:
80031
Fax:
- -
Introduction:
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Directors

Name
Position
Mary Szela
Chief Executive Officer, President; Director
Mats Wahlström
Chairman of the Board
Arjun Desai
Director
David J. Matlin
Director
Gary Gordon
Director
Kerry Hicks
Director
Sean Murphy
Director
William Valle
Director

Shareholders

Name
Position
Mary Szela
Chief Executive Officer, President; Director
David Patience
Chief Financial Officer
Bryan Cox
Chief of Research
Jennifer Stevens
Chief Regulatory Officer
Jodi Devlin
Chief of Clinical Operations
Richard Marshak
Chief Commercial Officer